Marstacimab在青少年与成人血友病患者中的临床药代动力学与药效学
本研究采用非线性混合效应模型,汇总6项临床试验中213名受试者的marstacimab及总TFPI浓度数据,建立TMDD模型与Emax PK/PD模型。结果显示体重是主要协变量,调整体重后年龄、种族、健康状态或轻度肝损伤无临床相关影响,且青少年与成人预测峰凝血酶水平一致,提示无需根据年龄或体重调整剂量。
要点
- 体重是marstacimab药代动力学的关键协变量。
- 调整体重后年龄、种族、健康状态或轻度肝损伤无临床相关影响。
- 青少年与成人模型预测峰凝血酶水平一致,无需按年龄或体重调整剂量。
核心结论
- TMDD模型结合Emax模型充分描述了marstacimab的药代动力学与药效学关系。
- PK/PD模拟表明无需根据年龄或体重调整给药方案。
研究设计与样本
- 采用非线性混合效应模型(NONMEM 7.5.0)分析6项临床试验中213名受试者的marstacimab和总TFPI浓度数据。
- 受试者包括健康志愿者63名和血友病患者150名,接受皮下注射marstacimab 30 mg至450 mg。
主要发现
- Marstacimab和总TFPI浓度通过具有非线性清除的靶点介导药物处置(TMDD)模型充分描述。
- 体重是关键结构协变量;调整体重后,年龄(青少年 vs 成人)、种族(亚洲 vs 非亚洲)、受试者状态(健康 vs 血友病)或轻度肝损伤无临床相关影响。
- 成人和青少年中观察到的峰凝血酶水平与模型预测值高度一致,人群间无临床相关差异。
关键数值与推荐
- 皮下注射marstacimab剂量范围为30 mg至450 mg。
- PK/PD模拟表明无需根据年龄或体重调整给药方案。
临床怎么用
- 临床使用marstacimab时无需根据年龄或体重进行剂量调整。
- 轻度肝损伤、种族差异或健康状态不影响marstacimab的临床相关暴露。
局限性
- 未报告重度肝损伤、肾功能不全等其他特殊人群的数据。
- 未报告药物相互作用或治疗药物监测相关信息。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: Marstacimab, a monoclonal antibody that targets tissue factor pathway inhibitor (TFPI), was developed for prophylactic treatment of hemophilia, with or without inhibitors. A nonlinear mixed-effects modeling approach was used to characterize plasma marstacimab and TFPI concentrations and identify covariates impacting marstacimab concentration. METHODS: Population modeling using nonlinear mixed-effects modeling (NONMEM) 7.5.0 software was performed with marstacimab and total TFPI concentration data pooled from 213 participants across 6 clinical trials including healthy volunteers (n = 63) and participants with hemophilia (n = 150). Participants received subcutaneous marstacimab at doses ranging from 30 mg to 450 mg. Plasma samples to determine marstacimab and total TFPI were analyzed using validated assays. An Emax pharmacokinetic (PK)/pharmacodynamic (PD) model was developed to link model-predicted free TFPI concentrations to peak thrombin. RESULTS: Marstacimab and total TFPI concentrations were adequately described with a target mediated drug disposition (TMDD) model with nonlinear clearance. Body weight was the key structural covariate. After adjusting for body weight, no clinically relevant effect of age (adolescent vs adult), race (Asian vs non-Asian), participant status (healthy vs hemophilia) or mild hepatic impairment was seen. There was good agreement between observed and model-predicted peak thrombin levels in adults and adolescents, with no clinically relevant differences between the populations. CONCLUSIONS: A TMDD model with first-order absorption and quasi-steady-state approximation adequately characterized marstacimab PK and total TFPI concentrations. An Emax model adequately described the relationship between model-predicted free TFPI and peak thrombin. The PK/PD simulation indicated that no changes in dosing regimen based on age or body weight were warranted. CLINICAL TRIALS REGISTRATION: ClinicalTrials.gov: NCT02531815, NCT02974855, NCT03363321, NCT03938792, NCT04832139, NCT04878731.
引用
- Nayak S, Suzuki A, Ravva P, et al. Clinical Pharmacokinetics and Pharmacodynamics of Marstacimab, an Anti-tissue Factor Pathway Inhibitor Monoclonal Antibody, in Adolescent and Adult Participants with Hemophilia. Clin Pharmacokinet. 2026. PMID: 42698050. doi:10.1007/s40262-026-01695-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。